Zealand Pharma
Tracked across 6 events · 73 articles · First seen Apr 19, 2026 · Last active Jun 29, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Tech
Impact: Zealand Pharma is presenting Phase 2 ZUPREME-1 data on petrelintide, a key drug candidate in its obesity and metabolic health pipeline, at a significant scientific conference. This presentation could enhance its reputation and potentially its stock value if the data is well-received.
May 27, 2026 · 19 articles
Business
Impact: Zealand Pharma is the company disclosing transactions in its shares by persons discharging managerial responsibilities and/or their closely associated persons.
May 29, 2026 · 6 articles
Business
Zealand Pharma A/S, a biotechnology company, is conducting a share buy-back program initiated on May 7, 2026, and set to conclude by October 31, 2026. The program allows for repurchasing shares up to DKK 1.3…
Impact: Zealand Pharma is executing a share buy-back program to repurchase its own shares, aiming to return value to shareholders and potentially increase earnings per share. The company has increased its share capital during the program.
May 26, 2026 · 30 articles
85
Zealand Pharma initiates share buy-backZealand Pharma Share...
40
Zealand Pharma appointed lead manager Danske BankZealand Pharma Share...
ERGEN INTELLIGENCE
Track Zealand Pharma live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard